Skip to content

Evaluating an Interactive Cancer Communication System (ICCS) in Lung Cancer

Interactive Cancer Communication System (ICCS) in Lung Cancer: Evaluating Survival Benefits. Center of Excellence in Cancer Communication Research: Using Technology to Enhance Cancer Communication and Improve Clinical Outcomes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01012401
Enrollment
284
Registered
2009-11-13
Start date
2009-11-30
Completion date
2014-05-15
Last updated
2019-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Stage IIIb or IV

Keywords

Lung cancer, Quality of life, Communication with physician

Brief summary

This study will examine the potential for an Interactive Cancer Communication System (ICCS) to impact not only psychosocial outcomes such as quality of life but also length of survival in an advanced stage lung cancer population. Two hypotheses will be tested: the Comprehensive Health Enhancement Support System- Lung Cancer (CHESS- LC) will significantly improve patient quality of life and length of overall survival as compared to a usual care control group.

Detailed description

The prognosis for Non-Small Cell Lung Cancer patients remains poor despite recent advances in anti-cancer therapies. A lung cancer diagnosis often inflicts fear, despair, and hopelessness on patients and loved ones. For lung cancer patients in particular, a population where palliation rather than cure is often the focus, interventions addressing communication about various types of suffering are crucial to quality of life (QOL). Our Center has done extensive research testing CHESS (Comprehensive Health Enhancement Support System), a non-commercial, web-based information and support system. The recent Clinician Integration Project tested the impact of CHESS versus an Internet only Control group on QOL for caregivers of advanced stage lung cancer patients. This study yielded an unanticipated finding that CHESS may have a survival benefit for patients as one year survival was significantly increased in the CHESS group (50%) compared to Internet (34.2%). As this project did not focus on patient outcomes, follow-up with a well-formulated study designed and powered to address specific hypotheses of the nature of this effect is critical. The proposed study will specifically test QOL and survival effects of CHESS on lung cancer patients. Using sites in Wisconsin, Connecticut,Houston, and Chicago, we will randomly assign 376 advanced lung cancer patients to two study arms: a patient control group receiving Usual Care (including access to a computer and Internet) and a group given access to the CHESS website. Patients may invite a caregiver to participate. Patients will be followed for 18 months or until patient death.

Interventions

OTHERCHESS website for lung cancer patient + internet access if needed

The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.

Sponsors

Hartford Hospital
CollaboratorOTHER
M.D. Anderson Cancer Center
CollaboratorOTHER
University of Illinois at Chicago
CollaboratorOTHER
National Cancer Institute (NCI)
CollaboratorNIH
University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients must be diagnosed with non-small cell lung cancer (Stage IIIA non surgical, IIIB or IV) * All patients must be within 12 months of their primary lung cancer diagnosis or metastatic or recurrence disease. * All patients must be at least 18 years of age, * All patients must have an ECOG Performance Status rating of level 0, 1 or 2. * If patients have brain metastases, they must be stable * All patients must be under the care of a clinician who has consented to participate in the study. * All patients must be able to speak and read English (educational attainment of at least 6th grade). * All patients will be invited to have a caregiver also participate in the study, however this is not required.

Design outcomes

Primary

MeasureTime frame
Compared to a Usual Care control, CHESS will significantly improve lung cancer patient Quality of Life.12-month intervention
Compared to a Usual Care control, CHESS will significantly improve patient influence length of survival of lung cancer patient.12-month intervention

Secondary

MeasureTime frame
Examine the effects of CHESS use on self-determination theory (SDT) constructs.12 mos.
Examine the factors that moderate effect of CHESS use on self-determination theory (SDT) constructs.12 mos.
Examine whether these constructs mediate the effects of CHESS use on patient quality of life.12 mos.
Examine whether treatment participation mediates the effect patient quality of life has on survival.12 mos/

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026